Neoadjuvant Radiotherapy Versus Surgery Alone for Stage II/III Mid-low Rectal Cancer With or Without High-risk Factors A Prospective Multicenter Stratified Randomized Trial

被引:27
|
作者
Deng, Xiangbing [1 ]
Liu, Ping [2 ]
Jiang, Dan [3 ]
Wei, Mingtian [1 ]
Wang, Xin [4 ]
Yang, Xuyang [1 ]
Zhang, Yuanchuan [5 ]
Wu, Bing [6 ]
Liu, Yanjun [5 ]
Qiu, Meng [4 ]
Zhuang, Hua [7 ]
Zhou, Zongguang [1 ]
Li, Yunfeng [2 ]
Xu, Feng [4 ]
Wang, Ziqiang [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu, Peoples R China
[2] Kunming Med Univ, Affiliated Hosp 3, Colorectal Canc Clin Res Ctr, Kunming, Yunnan, Peoples R China
[3] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
[4] Sichuan Univ, West China Hosp, Dept Abdominal Canc, Canc Ctr, Chengdu, Peoples R China
[5] Third Peoples Hosp Chengdu, Dept Gen Surg, Chengdu, Peoples R China
[6] Sichuan Univ, West China Hosp, Dept Radiol, Chengdu, Peoples R China
[7] Sichuan Univ, West China Hosp, Dept Ultrasound, Chengdu, Peoples R China
关键词
local recurrence; rectal cancer; risk stratification; short-course radiotherapy; total moserectal excision;
D O I
10.1097/SLA.0000000000003649
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: The aim of this study was to compare stage II/III rectal cancers with or without high-risk factors, and evaluate the effect of neoadjuvant radiotherapy (NRT) in these 2 cohorts. Background: NRT is often used in stage II/III rectal cancers to improve local control, while not affecting overall survival. However, good-quality surgery without NRT may also achieve good local control in selected patients. Methods: According to risk-stratification criteria and clinical staging, consecutive eligible participants of stage II/III rectal cancer were preoperatively classified into patients with (high-risk) or without (low-risk) high-risk factors. Both groups were respectively randomized to receive either short-course radiotherapy (SCRT) + total mesorectal excision (TME) or TME alone, forming the following 4 groups: high-risk patients with (HiR) or without (HiS) radiation, and low-risk patients with (LoR) or without (LoS) radiation. The primary endpoint was local recurrence. The secondary endpoints included overall survival, disease-free survival, distant recurrence, quality of surgery, and safety (NCT01437514). Results: In total, 401 patients were analyzed. With a median 54 months' follow-up, low-risk patients obtained better 3-year cumulative incidence of local recurrence (2.2% vs 11.0%, P = 0.006), overall survival rate (86.9%vs 76.5%, P = 0.002), disease-free survival rate (87.0% vs 67.9%, P < 0.001), and cumulative incidence of distant recurrence (12.5% vs 29.4%, P < 0.001) than high-risk patients. With regard to 3-year cumulative incidence of local recurrence, no differences were observed between the LoR and LoS groups (1.2% vs 3.0%, P = 0.983) or the HiR and HiS groups (12.9% vs 8.9%, P = 0.483). Conclusions and Relevance: Stratification of stage II/III rectal cancers according to risk factors to more precise subclassifications may result in noteworthy differences in survivals and local pelvic control. An extremely low cumulative incidence of local recurrence and survivals in low-risk patients can be achieved with upfront good quality of surgery alone. This trial, owing to the insufficient power, could not prove the noninferiority of surgery alone, but suggest a discriminative use of NRT according to clinical risk stratification in stage II/III rectal cancer.
引用
收藏
页码:1060 / 1069
页数:10
相关论文
共 50 条
  • [21] A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2)
    Jacob Lambdin
    Carrie Ryan
    Stephanie Gregory
    Kenneth Cardona
    Jonathan M. Hernandez
    Winan J. van Houdt
    Alessandro Gronchi
    Annals of Surgical Oncology, 2023, 30 : 4573 - 4575
  • [22] Acute Toxicities Comparison of Postoperative Chemoradiation Therapy With Capecitabine and Oxaliplatin Versus Capecitabine Alone for Pathological Stage II and III Rectal Cancer: A Randomized Multicenter Phase 3 Trial
    Ren, H.
    Liu, L.
    Feng, Y.
    Wang, W.
    Wang, J.
    Wang, J.
    Li, G.
    Li, G.
    Wang, W.
    Wang, S.
    Song, Y.
    Wang, X.
    Tang, Y.
    Li, N.
    Liu, Y.
    Fang, H.
    Yu, Z.
    Li, Y.
    Zhu, Y.
    Jin, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E172 - E173
  • [23] Low-Versus High-Risk Rectal Cancer Based on MRI Features: Outcomes in Patients Treated Without Neoadjuvant Chemoradiotherapy
    Jia, Xiao-Xuan
    Wang, Yi
    Cheng, Jin
    Yao, Xun
    Yin, Mu-jun
    Zhou, Jing
    Ye, Ying-Jiang
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2018, 211 (02) : 327 - 334
  • [24] Brazil-TNT: A Randomized Phase 2 Trial of Neoadjuvant Chemoradiation Followed by FOLFIRINOX Versus Chemoradiation for Stage II/III Rectal Cancer
    Bugano, Diogo Diniz Gomes
    Santos, Vanessa Montes
    Campos-Bragagnoli, Arinilda
    Melo, Julia Carole Medeiros
    Romagnolo, Luis Gustavo Capochin
    Neto, Osmar Barbosa
    Carvalho, Icaro Thiago
    Karassawa-Helito, Juliana
    Ortega, Cinthia D.
    Tridente, Cassia Franco
    Gerbasi, Lucas Soares
    Tustumi, Francisco
    Blasi, Poliana Bergamaschine Giovani
    de Araujo, Marleny Novaes Figueiredo
    Pandini, Rafael Vaz
    Seid, Victor Edmond
    Portilho, Ana Sarah
    Buosso, Albert
    Rolla, Fabiana
    de Paula Pinto Schettino, Guilherme
    Araujo, Sergio Eduardo Alonso
    CLINICAL COLORECTAL CANCER, 2024, 23 (03)
  • [25] Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: A prospective, multicenter, open-label, single arm phase II study.
    Kato, Takeshi
    Ikeda, Masataka
    Ikeda, Atsuyo
    Hasegawa, Junichi
    Ota, Hirofumi
    Shingai, Tatsushi
    Yasui, Masayoshi
    Fujii, Hitoshi
    Miyake, Yasuhiro
    Uemura, Mamoru
    Matsuda, Chu
    Satoh, Taroh
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Eguchi, Hidetoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study
    Mizushima, Tsunekazu
    Ikeda, Masataka
    Kato, Takeshi
    Ikeda, Atsuyo
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Satoh, Taroh
    Mori, Masaki
    Doki, Yuichiro
    BMC CANCER, 2019, 19 (01)
  • [27] Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study
    Tsunekazu Mizushima
    Masataka Ikeda
    Takeshi Kato
    Atsuyo Ikeda
    Junichi Nishimura
    Taishi Hata
    Chu Matsuda
    Taroh Satoh
    Masaki Mori
    Yuichiro Doki
    BMC Cancer, 19
  • [28] Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer
    Kulu, Yakup
    Tarantino, Ignazio
    Billeter, Adrian T.
    Diener, Markus K.
    Schmidt, Thomas
    Buechler, Markus W.
    Ulrich, Alexis
    ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (01) : 106 - 113
  • [29] Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer
    Yakup Kulu
    Ignazio Tarantino
    Adrian T. Billeter
    Markus K. Diener
    Thomas Schmidt
    Markus W. Büchler
    Alexis Ulrich
    Annals of Surgical Oncology, 2016, 23 : 106 - 113
  • [30] Neoadjuvant chemotherapy with or without oxaliplatin after short-course radiotherapy in high-risk rectal cancer: A subgroup analysis from a prospective study
    Kosakowska, Ewa
    Pietrzak, Lucyna
    Michalski, Wojciech
    Kepka, Lucyna
    Polkowski, Wojciech
    Jankiewicz, Malgorzata
    Cisel, Bogumila
    Krynski, Jacek
    Zwolinski, Jacek
    Wyrwicz, Lucjan
    Rutkowski, Andrzej
    Stylinski, Roman
    Nawrocki, Grzegorz
    Sopylo, Rafal
    Szczepkowski, Marek
    Tarnowski, Wieslaw
    Bujko, Krzysztof '
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2020, 25 (06) : 1017 - 1022